Navigation Links
Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
Date:9/18/2013

Exposure (LSE) technology. CT340 is IND-ready and first-in-human studies will commence in 2013.

Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced Management team, with over 100 years of combined R&D experience in pharma and biotech, and over 20 drug approvals. Creabilis has corporate and R&D functions in the UK and Italy.

About Pruritus and CT327

Chronic pruritus is a debilitating symptom of many dermatological diseases and has a significant impact on quality of life including sleep. It is the cardinal symptom in atopic dermatitis and one of the most important symptoms of psoriasis. There is no medicine currently approved for the topical treatment chronic pruritus and there is a significant unmet need for targeting treatment of chronic pruritus that combines efficacy with a good safety profile. CT327 inhibits TrkA kinase, the high affinity receptor for Nerve Growth Factor (NGF), and is believed to reduce the sensitisation of sensory neurons, a process which plays a pivotal role in the pathogenesis of pruritus.

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency.  Its goal is to accelerate economic growth by stimulating and supporting business-led innovation.  Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit http://www.innovateuk.org.

For further information please contact:

Creabilis
Eliot Forster
Email:

SOURCE Creabilis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
2. Creabilis Appoints Catherine Moukheibir to its Board of Directors
3. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
4. Neogen announces 1st quarter results conference call
5. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
6. The tranSMART Foundation Announces New Version of the tranSMART Open Source Data Sharing Platform for the Life Sciences Community
7. Emmaus Life Sciences Announces Closing Of $7.5 Million Private Placement
8. AEgis Technologies Announces Official Launch of ADME WorkBench Software for Pharmacokinetics Prediction
9. Probiotics for Eczema Leader Announces New Developments in Using Probiotics for Children’s Eczema Relief
10. Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO
11. CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 ... the Adult Stem Cell Technology Center, LLC ( ASCTC ... appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the ... gave the address at the 4th World Congress on ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Friday announced the availability of RFID 360, a ... major retailer and Department of Defense compliance. RFID 360 ... RFID implementation environment and schedule. , ,The first software ... others, is RFID Data Manager. Data Manager is designed ...
... engine company, set the business world abuzz with the ... so it released data about its financial performance that ... analysts however, criticized the company and its founders for ... proposed for its stock offering. While some trepidation is ...
... Note: The Wisconsin Technology Network is committed to ... and deployment of technology. We salute the administration and ... help spread the adoption health technology. If you ... should attend the following event. , ,The ...
Cached Biology Technology:RedPrairie announces RFID 360 compliance software 2Why Google Matters 2Why Google Matters 3The doctor is in: Thompson prescribes better health information technology 2The doctor is in: Thompson prescribes better health information technology 3The doctor is in: Thompson prescribes better health information technology 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... of chromosomes, and even a small change in this structure ... can lead to severe physical impairment. So it,s no ... frequently a contributing factor, says Prof. Ron Shamir of the ... Now Prof. Shamir and his former doctoral students Michal Ozery-Flato ...
... release is available in Spanish . ... because of their characteristics, produce a certain amount of social ... fact that they are subjected to moral conflicts and ethical ... very necessary from a social perspective, as in the case ...
... Institute scientist Matthias von Herrath, M.D., a world leader in ... seeing his discoveries translated into new therapies to better treat ... may soon get his chance as head of a new ... in 2012 by Novo Nordisk, a global healthcare company specializing ...
Cached Biology News:Patterns of chromosome abnormality: The key to cancer? 2Moral imagination as a key to overcoming work-related stigmas 2La Jolla Institute scientist takes quest to conquer Type 1 diabetes to the next level 2
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: